Skip to main content

Advertisement

SpringerLink
Log in

Can we restart the rituximab after remission of rituximab-induced interstitial lung disease in malignant lymphoma?

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Data availability

The clinical data supporting the conclusions of this manuscript will be made available by the authors.

References

  1. Kaegi C, Wuest B, Schreiner J, Steiner UC, Vultaggio A, Matucci A, Crowley C, Boyman O (2019) Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders. Front Immunol 10:1990. https://doi.org/10.3389/fimmu.2019.01990

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Verbsky JW, Hintermeyer MK, Simpson PM, Feng M, Barbeau J, Rao N, Cool CD, Sosa-Lozano LA, Baruah D, Hammelev E, Busalacchi A, Rymaszewski A, Woodliff J, Chen S, Bausch-Jurken M, Routes JM (2021) Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency. J Allergy Clin Immunol 147(2):704-712.e717. https://doi.org/10.1016/j.jaci.2020.07.021

    Article  CAS  PubMed  Google Scholar 

  3. González V, Salgueiro E, Jimeno FJ, Hidalgo A, Rubio T, Manso G (2008) Post-marketing safety of antineoplasic monoclonal antibodies: rituximab and trastuzumab. Pharmacoepidemiol Drug Saf 17(7):714–721. https://doi.org/10.1002/pds.1587

    Article  PubMed  Google Scholar 

  4. Cha SI, Choi KJ, Shin KM, Lim J, Yoo SS, Lee J, Lee SY, Kim CH, Park JY (2013) Risk factors for rituximab-induced interstitial lung diseases in patients with malignant lymphoma. Respiration; international review of thoracic diseases 85(2):175. https://doi.org/10.1159/000345211

    Article  PubMed  Google Scholar 

  5. Wagner SA, Mehta AC, Laber DA (2007) Rituximab-induced interstitial lung disease. Am J Hematol 82(10):916–919. https://doi.org/10.1002/ajh.20910

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Xiangyang No. 1 People’s Hospital, Hubei University of Medicine, Xiangyang, 441000, China

    Dongdong Zhang, Yidi Han & Youhong Dong

Authors
  1. Dongdong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yidi Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Youhong Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dongdong Zhang.

Ethics declarations

Ethics committee approval

This study was approved by the Ethics and Scientific Committee of Hubei University of Medicine (XYY2021002) and was performed according to the Good Clinical Practice Guidelines and the Helsinki Declaration.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, D., Han, Y. & Dong, Y. Can we restart the rituximab after remission of rituximab-induced interstitial lung disease in malignant lymphoma?. Ann Hematol 101, 2373–2375 (2022). https://doi.org/10.1007/s00277-022-04913-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-022-04913-9

Search

Navigation